Cost-Effectiveness Analysis of Gefitinib Plus Chemotherapy versus Gefitinib Alone for Advanced Non-Small-Cell Lung Cancer with EGFR Mutations in China-Reference-Cited by-同舟云学术

Cost-Effectiveness Analysis of Gefitinib Plus Chemotherapy versus Gefitinib Alone for Advanced Non-Small-Cell Lung Cancer with EGFR Mutations in China

Published:2021-11 Issue: Volume:Volume 13 Page:8297-8306
ISSN:1179-1322
Container-title:Cancer Management and Research
language:en
Short-container-title:CMAR

Author:

Shu Yamin,Zhang Qilin,He Xucheng,Chen Li

Publisher

Informa UK Limited

Subject

Oncology

Reference32 articles.

1. Cancer Statistics, 2021

2. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries

3. Cancer statistics in China, 2015

4. Current cancer situation in China: good or bad news from the 2018 Global Cancer Statistics?

5. Precision Diagnosis and Treatment for Advanced Non–Small-Cell Lung Cancer

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cost-effectiveness of sotorasib as a second-line treatment for non-small cell lung cancer with KRASG12C mutation in China and the United States;Frontiers in Pharmacology;2024-06-14

2. Pharmacokinetics, bioequivalence, and safety studies of gefitinib tablet formulations: A randomized, open-label, two-period, two-sequence crossover study in Chinese healthy volunteers;Journal of Drug Delivery Science and Technology;2023-06

3. Rapamycin-regulated autophagy through mitochondrial function in lung carcinoma A549 cells;2023-01-31

4. Cost-effectiveness of nivolumab plus ipilimumab versus chemotherapy as first-line therapy in advanced non-small cell lung cancer;International Immunopharmacology;2023-01

5. Cost-effectiveness of osimertinib versus standard EGFR-TKI as first-line treatment for EGFR-mutated advanced non-small-cell lung cancer in China;Frontiers in Pharmacology;2022-09-20